Keywords: alnylam, loss, rockets, expenses, usa-based, rnai, therapeutics

Alnylam's loss rockets on R&D expenses

Article | 11 May 2009

Print This

USA-based RNAi therapeutics company Alnylam's first-quarter loss rocketed as higher R&D costs failed to be balanced by increased revenue.

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in